罕见病治疗再获突破,复星一款自研创新药获批临床试验

凤凰网财经
09 Apr

近日,复星旗下浙江星浩澎博医药有限公司收到国家药品监督管理局关于同意XH-S003胶囊(申请注册分类:化药1类;以下简称“XH-S003”)用于治疗阵发性睡眠性血红蛋白尿症(PNH)开展临床试验的批准。星浩澎博拟于条件具备后于中国境内(不包括港澳台地区,下同)开展II期临床试验。XH-S003为复星医药自主研发的补体系统小分子抑制剂,拟用于治疗补体异常激活相关的疾病。XH-S003作为特异性的补体...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10